Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
VTYX Price/Volume Stats
Current price | $2.46 | 52-week high | $47.25 |
Prev. close | $2.50 | 52-week low | $1.87 |
Day low | $2.44 | Volume | 851,100 |
Day high | $2.52 | Avg. volume | 1,896,409 |
50-day MA | $2.28 | Dividend yield | N/A |
200-day MA | $21.37 | Market Cap | 145.26M |
VTYX Stock Price Chart Interactive Chart >
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Latest VTYX News From Around the Web
Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare ConferenceSAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference. Event: 35th Annual Piper Sandler Healthcare ConferenceLocation: New York, NYDate: Tuesday, November 28, 202 |
Ventyx Biosciences to Participate in the Jefferies London Healthcare ConferenceSAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceLocation: London, United KingdomDate: Thursday, November 16, 2023Time: |
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate ProgressVentyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third qu |
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a TurnaroundVentyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
PTON Stock Slumps as Deutsche Bank Downgrades PelotonPeloton stock is taking a beating on Tuesday after shares of PTON were downgraded and saw their price target reduced by Deutsche Bank. |
VTYX Price Returns
1-mo | 24.87% |
3-mo | 5.58% |
6-mo | -92.42% |
1-year | -94.45% |
3-year | N/A |
5-year | N/A |
YTD | -0.40% |
2023 | -92.47% |
2022 | 65.11% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...